---

A study on appropriate use and stewardship of proton pump inhibitors

---

Original Article

Author Details : Naresh Mondal*, Shilpi Maity, Alamki Phawa, Bireswar Roy, E. Satheesh Kumar, Narayana Swamy V.B

Volume : 11, Issue : 1, Year : 2024

Article Page : 56-61

https://doi.org/10.18231/j.ijpp.2024.010

Suggest article by email

Get Permission

---

Abstract

Objective: To analyze the prescribing pattern of use of PPI with respect to “FDA-Approved Indications and Doses for PPI Therapy.” Materials and Methods: After obtaining approval from the Institutional Ethics Committee, a cross-sectional study was carried out among 400 inpatients in a tertiary care hospital in Bangalore. The data were collected from the patient case profile and prescriptions and noted in a self-designed data collection form. The statistical analysis of the collected data was performed using SPSS software and Excel. Results: The study, conducted on 400 patients, revealed a male majority (60%) and a female representation of 40%. Proton Pump Inhibitors (PPIs), mainly Pantoprazole (74.70%), were frequently prescribed, notably in General Medicine (220 patients). PPI use was generally appropriate: indication (99%), dose (97%), frequency (92.8%), and duration (91.8%). However, irrational prescriptions were noted: indication (1%), dose (3%), frequency (7.3%), and duration (8.3%). 139 drug interactions were identified, categorized into Major (39.6%), Moderate (46%), and Minor (14.4%). For example, Ondansetron and tramadol exhibited a major interaction. Among PPI combinations, 93.75% could affect CYP2C19 metabolism, and 6.3% had additive/synergistic toxicity potential.

Keywords: Proton Pump Inhibitors, Non­Steroidal Anti­Inflammatory Drugs, Cytochrome P0 45219 C

How to cite : Mondal N, Maity S, Phawa A, Roy B, Kumar E S, V.b N S, A study on appropriate use and stewardship of proton pump inhibitors. Indian J Pharm Pharmacol 2024;11(1):56-61

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.